HSP90AA1 and cancer: DEBIO‐0932 administration at 160 mg/kg during the following 3 weeks significantly impaired the growth of both brain metastases and extracranial lesions (Figs 4B–G and EV2F–H) by targeting HSP90 in cancer cells (Fig EV2A–D; Bagatell et al, 2000).